- The tepid ZFN data-stoked selloff in Sangamo Therapeutics is weighing on other gene therapy players. CRISPR/Cas9 gene editors Editas Medicine (EDIT -8.3%), CRISPR Therapeutics (CRSP -9%) and Intellia Therapeutics (NTLA -7.6%) appear to be under the most pressure.
- Selected tickers: (AXON -11.7%)(AVRO -6%)(MGTX -1.3%)(BLUE -3.9%)(GNPX -6.5%)(FIXX -2.6%)(XON -5.7%)(FCSC +1.6%)(RCKT -3.1%)(ABEO -9.7%)(CAPR -2.2%)(NITE +2.5%)(SRPT -3.2%)(ZIOP -5.2%)(FLXN -4.6%)(RGNX -2.4%)(BMRN -2.6%)(BOLD -4.6%)(RARE -4.3%)(QURE -1.5%)(VYGR -2.9%)(BNTC -0.7%)(KRYS +3.7%)(ONCE -3.5%)(ADVM -2.7%)
Sangamo selloff weighs on gene therapy developers
Editas Medicine, Inc. (EDIT) Stock, CRSP Stock, NTLA Stock, AXON-OLD Stock, AVRO Stock, MGTX Stock, BLUE Stock, GNPX Stock, QTTB Stock, PGEN Stock, FCSC Stock, RCKT Stock, ABEO Stock, CAPR Stock, NITE Stock, SRPT Stock, TCRT Stock, PCRX Stock, RGNX Stock, BMRN Stock, BOLD Stock, RARE Stock, QURE Stock, VYGR Stock, BNTC Stock, KRYS Stock, RHHBY Stock, ADVM StockDouglas W. House, 17 Comments